Key facts
- Kneu Health’s last known valuation is $18.9M (Oct 2025).
- It has raised $11.3M; the latest was Seed Round ($5.6M) in Oct 2025.
- Notable investors include Techstars, Texas Medical Center, University of Oxford, Oxford Science Enterprises, Alzheimer's Society — 11 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for Kneu Health
- ·The full record, as it builds
Funding rounds
No funding rounds for Kneu Health are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Kneu Health
Developer of a smartphone-based clinical platform designed to provide personalized care for Parkinson's disease and dementia. The company's platform uses artificial intelligence to monitor and translate digital measures of clinically relevant symptoms, optimizing condition management, reducing clinician burden, and ultimately improving outcomes, enabling clinicians and caregivers to provide efficient and effective care to patients.
- Sector
- Healthcare
- HQ
- London, United Kingdom
- Founded
- 2022
- Employees
- 20
- Website
- kneu.com/
- Ownership
- Privately Held (backing)
Kneu Health doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Kneu Health shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Kneu Health in its N-PORT filings yet. We sweep new filings monthly.